Equities Analysts Issue Forecasts for Prothena Q1 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Research analysts at Zacks Research boosted their Q1 2025 earnings estimates for Prothena in a research report issued on Wednesday, March 12th. Zacks Research analyst E. Bagri now expects that the biotechnology company will post earnings per share of ($1.06) for the quarter, up from their previous estimate of ($1.33). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($3.76) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.28) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($4.04) EPS.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The company had revenue of $2.12 million for the quarter, compared to analyst estimates of $7.53 million.

A number of other equities analysts also recently commented on the stock. Royal Bank of Canada reduced their price objective on shares of Prothena from $24.00 to $20.00 and set a “sector perform” rating for the company in a report on Friday, February 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $48.00 price objective on shares of Prothena in a research note on Friday, February 21st. Chardan Capital restated a “buy” rating and set a $40.00 target price on shares of Prothena in a research report on Friday, February 21st. Finally, Oppenheimer upped their price target on Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a research report on Friday, February 7th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Prothena Price Performance

Shares of PRTA stock opened at $13.74 on Monday. Prothena has a one year low of $11.70 and a one year high of $26.75. The stock has a fifty day moving average price of $14.41 and a 200 day moving average price of $16.04. The stock has a market cap of $739.58 million, a P/E ratio of -5.97 and a beta of -0.02.

Hedge Funds Weigh In On Prothena

Institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP lifted its position in Prothena by 22.8% during the 4th quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company’s stock worth $71,063,000 after buying an additional 952,088 shares in the last quarter. Boxer Capital Management LLC acquired a new position in shares of Prothena during the fourth quarter worth approximately $9,556,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Prothena by 1,122.9% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock valued at $8,812,000 after purchasing an additional 483,673 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Prothena by 84.3% in the fourth quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company’s stock valued at $10,335,000 after purchasing an additional 341,274 shares in the last quarter. Finally, Finepoint Capital LP raised its position in Prothena by 51.6% in the 4th quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company’s stock worth $9,100,000 after purchasing an additional 223,600 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.